Vaccines, Inactivated

• 

  Subject Areas on Research

  • AIDS response. 
  • An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults. 
  • Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. 
  • Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children. 
  • Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants. 
  • Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. 
  • Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. 
  • Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. 
  • Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes. 
  • Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. 
  • Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. 
  • Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. 
  • Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. 
  • Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model. 
  • Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh. 
  • Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. 
  • Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. 
  • Poliovaccine policy--time for a change. 
  • Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. 
  • Race-related differences in antibody responses to the inactivated influenza vaccine are linked to distinct pre-vaccination gene expression profiles in blood. 
  • Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. 
  • Recommendations for Prevention and Control of Influenza in Children, 2019-2020. 
  • SIV vaccine protection of rhesus monkeys. 
  • Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. 
  • Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. 
  • Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. 
  • Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. 
  • Systems biology of vaccination for seasonal influenza in humans. 
  • The ability of certain SIV vaccines to provoke reactions against normal cells. 
  • The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children. 
  • The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged. 
  • Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study. 
  • Ultraviolet-light-inactivated Cas-Br-M murine leukemia virus induces a protective CD8+ cytotoxic T lymphocyte response in newborn mice. 
  • Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans.